BRAF and familial atrioventricular septal defect: The pharmacological targeting of the V600E BRAF mutation by the drug vemurafenib repeatedly yielded dramatic clinical benefit in a significant portion of patients, unparallel to that of any other agent attempted in the treatment of ECD.